We are glad to learn that the subject of 'donors as research subjects' attracts attention, as evidenced by commentaries on our recent article 1 from Apperley, 2 Appelbaum 3 and Craddock. 4 It is a challenge to set guidelines and recommendations for deciding when an unrelated stem cell donor becomes a research subject, as there are no absolute criteria and the question is subject to individual national regulations. Our article underlines that it is not often that an unrelated donor is a research subject, despite the fact that most patients are transplanted according to a research transplant protocol. The majority of these protocols include both research activities and standard of care, and most often the donor is only participating in the therapeutic activities. It is a rather rare exception when the donor participates in the research activities and becomes a research subject. We try to identify such instances and suggest how to proceed. We also urge donor registries to assist transplant centers to perform investigational transplants and to find ways to minimize time-consuming obstacles-either in accordance with the criteria mentioned in our article or because of the national regulations or local policy.
Apperley discusses a situation that may make the donor a research subject, referring to a request for 'higher than normal cell counts'. She asks whether the number of cells needed for a T-cell depleted or CD34-positive cell selection transplant would fall into this category, and thus require individual registry research approval and donor consent to research. We would argue that in this circumstance, the donor is only participating in the standard of care aspects of the protocol and would not be a research subject. T-cell depletion and CD34-positive cell selection are well-established procedures that are routinely performed as part of a standard donation, where the need for a high cell number is well documented in the literature. Such a request of a donor would not be unusual, even in the absence of a research protocol, and may be considered in the accepted range of therapeutic requests. What we are referring to in our article is that a donor is a research subject only if a collection requires 'higher than normal cell counts because of the requirements of the research', that is, instances when the request exceeds 'normal cell counts' (even for T-cell depletion and CD34-positive cell selection) and the cell number aspect is crucial to the research transplant protocol. However, whether the donor is a research subject or not, it is important to underline that the donor always has the right to know about all aspects of the donation before consenting to donate, including why a requested cell number is high.
Likewise a number of different conditioning regimens, transplant modalities and DLI protocols exists where the only donor activity is to participate in cell donation. Modification or comparison of these entities is frequently a key subject in research transplant protocols but, because the donors are only providing a standard donation, they are not research subjects. We therefore state in our article that 'donors should not be considered research subjects just by virtue of donating stem cells for a patient who is being transplanted on a research protocol'. In addition, the standard World Marrow Donor Association (WMDA) work up request forms include sections related to these entities, allowing the registry to be aware of transplant aspects that potentially could evoke donor-related issues, such as requests for second donations, and possible need for the registry to ask for more information. Some of these instances would only imply that the donor would have to be informed and provide standard consent. Perhaps a key question should be: could such a request be reasonably made in the absence of a research protocol-if the answer is 'yes', the donor is unlikely to be a research subject. However, other research protocols may involve donor activities that are research, and these protocols will require research approval and donor consent to research. Research protocols implying generating MSCs or tumor-or viral-specific T-cell lines, and probably also certain DLI protocols in which the product is experimentally manipulated or a prerequisite for the research transplant protocol would make the donors research subjects.
WMDA are publishing recommendations and guidelines for a global exchange of cell products and blood samples from unrelated donors. National and supranational (for example, the European Union) regulations vary between countries and regions, including those regulating export and import of donor cell products. In many countries, analyses of exported blood samples from stem cell donors are limited to standard donor transplantation immunology evaluation and selection, which would include HLA typing, blood group typing, HLA-Ab titration, titration of antibodies against blood groups, infectious disease marker analyses relevant for SCT, and perhaps also KIR typing, cytokine polymorphism and cytotoxic T-lymphocyte precursor frequency. Thus, analyses for other parameters, such as for instance gene markers, such as delta32 mutations of the CCR5 gene, or NOD2 (nucleotidebinding oligomerization domain containing 2) testing, would need approval by the appropriate health authorities for research as well as donor consent for research, as would generation of donor-derived cell lines for therapeutic purposes. Several WMDA standards (3.05.4, 6.05.1, 6.05.2, 9.05) deal with these issues. As noted by Appelbaum, these issues are likely to generate additional discussion in the coming years.
As every new protocol in which the donor is a research subject would be cumbersome for the registry to deal with, and thus would potentially slow down the transplant program and jeopardize the patient, we recommend in our article that registries try to set up mechanisms for rapid management of donor work up where the donor would be regarded as a research subject. How this is carried out will probably vary between countries and regions, but may be feasible for some and difficult for others. For the latter ones, it seems worthwhile to contact the respective regulators in order to remove undue regulatory burdens as Apperley describes for the situation in the European Union.
It is our hope and prediction that future international stem cell donations for research purposes will take place smoothly and efficiently, even when all aspects of donors' rights and integrity and national and supranational regulations are taken into account. To achieve this, we have to be aware of and prepared for the challenges, in an attempt to avoid cumbersome obstacles. We agree with Apperley that the opinions and involvement of donors should be actively solicited in addressing these issues.
